Publications by authors named "Hong-Min Pan"
J Hematol Oncol
November 2024
Article Synopsis
- There is a clinical need to improve the effectiveness and safety of current anti-PD-1/PD-L1 cancer immunotherapy, leading to the study of IBI318, a novel bispecific antibody targeting PD-1 and PD-L1 in patients with advanced tumors.
- The clinical trial consisted of two phases: Phase Ia focused on dose escalation to find the optimal dosage, while Phase Ib evaluated safety and efficacy in patients with non-small cell lung cancer and nasopharyngeal carcinoma.
- Results showed that IBI318 had a good safety profile with an objective response rate of 15.5% overall, and higher rates in treatment-naïve patients: 45.5% for NSCLC and 30.0% for
